When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Prolactinoma

Last reviewed: 22 Jul 2025
Last updated: 22 Jul 2022

Summary

Definition

History and exam

Key diagnostic factors

  • presença de fatores de risco
  • amenorreia ou oligomenorreia
  • infertilidade
  • galactorreia
  • perda do desejo sexual (libido)
  • disfunção erétil
  • deterioração visual (por exemplo, hemianopsia temporal)
Full details

Other diagnostic factors

  • osteoporose
  • oftalmoplegia
  • cefaleias
Full details

Risk factors

  • predisposição genética (por exemplo, presença de mutação resultando em neoplasia endócrina múltipla-1 [NEM-1], adenoma hipofisário familiar isolado [FIPA])
  • terapia estrogênica
  • sexo masculino, de 30 a 60 anos de idade
  • sexo feminino, de 20 a 50 anos de idade
Full details

Diagnostic tests

1st tests to order

  • prolactina sérica
  • ressonância nuclear magnética (RNM) da hipófise
  • exame do campo visual computadorizado
Full details

Treatment algorithm

ONGOING

mulheres na pré-menopausa

mulheres menopausadas

homens

Contributors

Authors

Niamh Martin, MB ChB, PhD, FRCP

Reader in Endocrinology

Imperial Centre for Endocrinology

Department of Metabolism, Digestion and Reproduction

Imperial College London

London

UK

Disclosures

NM declares that she has no competing interests.

Acknowledgements

Dr Niamh Martin would like to gratefully acknowledge Dr Ilan Shimon, the previous contributor to this topic.

Disclosures

IS receives consultancy and lecturing fees from Pfizer, Israel, and is an author of a number of references cited in this topic.

Peer reviewers

Mark Molitch, MD

Professor

Division of Endocrinology

Northwestern University Feinberg School of Medicine

Chicago

IL

Disclosures

MM is an author of a number of references cited in this topic.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Wildemberg LE, Fialho C, Gadelha MR. Prolactinomas. Presse Med. 2021 Dec;50(4):104080.Full text  Abstract

Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.Full text  Abstract

Xia MY, Lou XH, Lin SJ, et al. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018 Jan;59(1):50-61. Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Prolactinoma images
  • Differentials

    • Macroadenomas hipofisários não funcionantes
    • Hiperprolactinemia induzida por medicamentos
    • Hipotireoidismo primário
    More Differentials
  • Guidelines

    • Position statement for clinical practice: prolactin-secreting tumors
    • ACR appropriateness criteria: neuroendocrine imaging
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer